By Karlee Weinmann ( July 30, 2014, 1:25 PM EDT) -- AstraZeneca PLC said Wednesday it would pay up to $2.1 billion for the rights to respiratory drugs developed by Almirall SA, showcasing its deal-making prowess and bright prospects as a stand-alone company after it spurned a blockbuster tie-up bid from rival Pfizer Inc....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.